Cargando…

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights

Sorafenib, a multi-kinase inhibitor with antiangiogenic, antiproliferative, and proapoptotic properties, is the first-line treatment for patients with late-stage hepatocellular carcinoma (HCC). However, the therapeutic effect remains limited due to sorafenib resistance. Only about 30% of HCC patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Xinchen, Yan, Tinghao, Liu, Fen, Liu, Qingbin, Zhao, Jing, Xiong, Huabao, Jiang, Shulong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441942/ https://www.ncbi.nlm.nih.gov/pubmed/36071839 http://dx.doi.org/10.3389/fphar.2022.991052

Ejemplares similares

Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis
por: Yin, Xiu, et al.
Publicado: (2022)

The emerging role of circular RNAs in drug resistance of non-small cell lung cancer
por: Yan, Tinghao, et al.
Publicado: (2022)

Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease
por: Zhang, Ni, et al.
Publicado: (2023)

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis
por: Liu, Zhi-Yong, et al.
Publicado: (2022)

Therapeutic effect and transcriptome-methylome characteristics of METTL3 inhibition in liver hepatocellular carcinoma
por: Liu, Qingbin, et al.
Publicado: (2023)

Effects of Glycolysis-Related Genes on Prognosis and the Tumor Microenvironment of Hepatocellular Carcinoma
por: Zheng, Ju-Yan, et al.
Publicado: (2022)

Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
por: Leineweber, Can G., et al.
Publicado: (2023)

Sorafenib-Induced Autophagy Promotes Glycolysis by Upregulating the p62/HDAC6/HSP90 Axis in Hepatocellular Carcinoma Cells
por: Yan, Xiaoyu, et al.
Publicado: (2022)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
por: Wu, Ying, et al.
Publicado: (2020)

Activation of FcRn Mediates a Primary Resistance Response to Sorafenib in Hepatocellular Carcinoma by Single-Cell RNA Sequencing
por: Guan, Xin, et al.
Publicado: (2021)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Li, Yan, et al.
Publicado: (2022)

Comprehensive analysis of immunogenic cell death associated genes expression, tumor microenvironment, and prognosis in hepatocellular carcinoma
por: Xiang, Jiankang, et al.
Publicado: (2023)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Gehua Jiecheng Decoction Inhibits Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice by Improving Tumor Immunosuppression Microenvironment
por: Cheng, Changpei, et al.
Publicado: (2020)

OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53
por: Omar, Hany A., et al.
Publicado: (2016)

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells
por: He, Wubin, et al.
Publicado: (2021)

An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment
por: Du, Yingxi, et al.
Publicado: (2021)

Roles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer
por: Liu, Qi, et al.
Publicado: (2022)

Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma
por: Chen, Siqi, et al.
Publicado: (2023)

Environmental Stressors on Skin Aging. Mechanistic Insights
por: Parrado, Concepcion, et al.
Publicado: (2019)

Mechanistic Insight into PPARγ and Tregs in Atherosclerotic Immune Inflammation
por: Gao, Zhao, et al.
Publicado: (2021)

Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study
por: Abdelmageed, Mai M., et al.
Publicado: (2016)

RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma
por: Peng, Hao, et al.
Publicado: (2022)

Editorial: New mechanistic insights into cancer precision medicine
por: Kwok, Hang Fai
Publicado: (2023)

Emerging mechanistic insights of selective autophagy in hepatic diseases
por: Alim Al-Bari, Abdul, et al.
Publicado: (2023)

Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
por: Wei, Jingyao, et al.
Publicado: (2021)

Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing
por: Ullah, Hammad, et al.
Publicado: (2018)

M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy
por: Zhao, Kun, et al.
Publicado: (2022)

Editorial: Vitamin D and COVID-19: New Mechanistic and Therapeutic Insights
por: Marcinkowska, Ewa, et al.
Publicado: (2022)

Mechanistic insights into the role of plant polyphenols and their nano-formulations in the management of depression
por: Kabra, Atul, et al.
Publicado: (2022)

Micro-simulation insights into the functional and mechanistic understanding of glycyrrhizin against asthma
por: Qi, Jian-Hong, et al.
Publicado: (2023)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
por: Kong, Fan-Hua, et al.
Publicado: (2021)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma
por: He, Yuchao, et al.
Publicado: (2023)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9qglhn6dhcjvhvl99ncmob0kli